What a Romanian cohort study found about kidney stones and GLP-1 therapy
A single-center retrospective study followed 126 adults on semaglutide or tirzepatide and reported that 10.3% had a documented kidney stone recurrence after starting therapy. The design cannot say whether the medication caused those events.
A study published in the Journal of Clinical Medicine looked at people who had a history of urinary stones and later started a GLP-1-based medication. The researchers wanted to describe how often stones came back after treatment began.
This was a study in humans, not animals or cells. It was retrospective, meaning the authors reviewed existing medical records rather than running a planned experiment. It was also single-center and had no comparison group of untreated patients.
Who was studied
The researchers started by screening 168 adults receiving either semaglutide or tirzepatide. They then removed certain people to tighten the group: four who had prior bariatric surgery, 33 without at least six months of follow-up after starting treatment, and five with hyperparathyroidism. That left 126 participants.
Of those, 94 were taking semaglutide and 32 were taking tirzepatide. The median follow-up was 9 months, with most people followed between 8 and 12 months.
What the study required to count a recurrence
To be counted, a patient needed a stone episode documented before starting the medication and a new symptomatic or radiologically progressive stone event afterward. In plain terms, these were people with known stone history whose stones returned or worsened on imaging after treatment began.
What the researchers reported
Thirteen patients, or 10.3% of the group, had a recurrent stone episode after starting GLP-1-based therapy. The confidence interval ranged from about 6% to 17%, which reflects the uncertainty that comes with a small sample.
Notably, the authors could not find any measured factor that clearly separated the people who had recurrences from those who did not. That included demographic, metabolic, renal, hydration-related, electrolyte, and treatment characteristics. Allopurinol use appeared more often among those with recurrences, but the authors called this exploratory and likely influenced by why those patients were prescribed it in the first place.
What this does and does not establish
This study describes events that happened after treatment started. It does not show that the medication caused them. The authors are direct about this limitation. Because there was no untreated comparison group, no analysis of stone rates before treatment, no standardized schedule of imaging, and incomplete data on medication exposure, the study cannot estimate how much risk, if any, is attributable to the treatment itself.
People with a prior stone history can form new stones over time regardless of medication. Without a comparison group, there is no way to know whether 10.3% is higher, lower, or about the same as what these patients would have experienced anyway.
What this means if you are considering treatment
If you have a personal history of kidney stones, this study is a reminder to discuss that history openly with a clinician before starting any new medication. It does not tell you to avoid treatment, and it does not tell you treatment is safe for your situation. It simply reports what one group of patients experienced and acknowledges what it cannot answer.
Both medications named in the study are ones Live Vital offers under physician supervision: semaglutide and tirzepatide. Outcomes vary by individual, and these are prescription treatments, not consumer products.
If this is relevant to you, any GLP-1-based therapy at Live Vital requires a medical intake and physician approval. Dr. Patrick Taylor reviews each case, and you can begin that process at get started. A prescription is never guaranteed. This article is general information, not medical advice.